IDEX Corporation Q2 FY26 Earnings Analysis

Published 29 May 2026 | Machinery | Market Cap: ₹15.5K Cr

Price

210.03

Market Cap

₹15.5K Cr

P/E Ratio

31.2

Revenue Rank

Rank 3

Margin Rank

Rank 3

Earnings Summary

- Positive long-term growth expected, particularly beyond 2026, with strong involvement in emerging technologies and markets (Page 13). - IDEX expects continued solid growth beyond 2026, especially driven by its Health & Science Technologies (HST) segment with high single-digit to double-digit growth.

📊 Revenue & Sales Performance

Rank 3

- Positive long-term growth expected, particularly beyond 2026, with strong involvement in emerging technologies and markets (Page 13). - HST segment driving high single-digit to double-digit growth, supported by backlog expansion and advantaged markets like semiconductor, data centers, and space & defense (Pages 4, 8). - FMT showing solid performance with strong water platform growth, but overall flat outlook due to macro uncertainties (Pages 4, 7). - FSDP experiencing slight decline but with pockets of growth in fire and safety (Page 4). - Overall organic revenue growth guidance for 2026 revised upward to 3%-4%, with HST growth offsetting flatter FMT and FSDP (Page 3). - Continued innovation and multiple entry points into growth markets, including optical switching, thermal management, and AI-integrated water solutions (Page 13).

📈 Profitability & Margins

Rank 3

- IDEX expects continued solid growth beyond 2026, especially driven by its Health & Science Technologies (HST) segment with high single-digit to double-digit growth. - Full year 2026 guidance raised to 3-4% organic growth, up from 1-2%, driven by strong HST momentum and stable outlooks in other segments. - Adjusted EBITDA margin for 2026 expected to be 26.5% to 27%, with margin expansion in HST partially offset by challenges in other segments. - Adjusted EPS guidance for 2026 increased by $0.20 to a range of $8.35 to $8.55, representing mid- to high single-digit growth year-over-year. - Incremental margins in HST are currently in the low to mid-30% range, expected to improve as acquired businesses scale and life sciences growth picks up. - Beyond 2026, investments in advantaged markets like space, data centers, and semiconductors provide a strong runway for sustained earnings growth.

🏗️ Capital Expenditure Plans

Yes

- IDEX expects an increase in CapEx for 2026, supporting overall growth, especially in the HST segment and some other growth platforms (Pages 13-14). - The rise in CapEx aligns with growth rates increasing rather than a shift toward more capital-intensive operations (Page 14). - There are no major single large CapEx projects; investments are spread across various businesses with a focus on equipment and automation to support growing demand (Pages 13-14). - The company emphasizes investments in technology and innovation with relatively low capital intensity, enabling agility and faster technology deployment, particularly in space and defense sectors (Page 14). - Internal optimization through the "8020" initiative helps offset CapEx increases by reallocating capital from lower-growth areas to faster-growing applications (Page 13). - IDEX continues to pursue bolt-on tuck-in acquisitions to expand advantaged market presence and capabilities (Page 14).

💰 Fundraising & Capital Structure

No information

- There is no mention of any new fundraising through debt or equity in the provided transcript. - The company ended Q1 2026 with strong liquidity of approximately $1.1 billion. - Their gross leverage ratio is roughly 2x as of the end of Q1 2026. - They maintain a balanced capital deployment strategy focusing on organic investments, bolt-on M&A, and returning capital to shareholders. - They repurchased $76 million of shares in the quarter and plan to maintain this repurchase pace through 2026. - No indications given of plans to issue new debt or equity in the near term; emphasis is on managing growth with current resources and maintaining a strong balance sheet for flexibility.

📋 Order Book & Pipeline

Yes

- HST segment showed strong backlog growth, driven by faster-growing order wins and novel solutions in advantaged markets like semiconductor OEM and data centers. - Increased visibility into order backlog, with customers providing good forward-looking insights for capital and resource planning. - Backlog growth supports confidence in continued growth beyond a 12-month horizon. - FMT and FSDP have less visibility due to the rapid fulfillment nature of their businesses. - Overall, organic orders grew approximately 10% in the quarter, led by HST's 17% order growth year-over-year. - Orders in FMT grew 9% organically; FSDP orders declined 4% organically. - Approximately 50% of orders are typically booked entering any quarter, with strong HST order activity building backlog for better financial outlook.

Key Metrics

Revenue

Rank 3

Margin

Rank 3

Capex

Yes

Fundraise

No information

Order Book

Yes

Frequently Asked Questions

What were IDEX Corporation Q2 FY26 results?

- Positive long-term growth expected, particularly beyond 2026, with strong involvement in emerging technologies and markets (Page 13). - IDEX expects continued solid growth beyond 2026, especially driven by its Health & Science Technologies (HST) segment with high single-digit to double-digit growth.

What is IDEX Corporation share price analysis?

IDEX Corporation currently shows a below-average growth signal. The stock trades at a P/E of 31.2 with a market cap of $15,545. Investors should review the full earnings analysis for detailed insights.

Is IDEX Corporation planning capital expenditure?

- IDEX expects an increase in CapEx for 2026, supporting overall growth, especially in the HST segment and some other growth platforms (Pages 13-14).

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.